P. Pronzato

6.9k citations

231 papers · 4.4k indexed · 1 hit paper · h-index 32

Impact in

Oncology top 1%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
Reproductive Medicine top 1%
- Ovarian function and disorders

Papers in

Oncology 165
- Cancer Treatment and Pharmacology 77
- HER2/EGFR in Cancer Research 24
- Neutropenia and Cancer Infections 22
- Lung Cancer Research Studies 19
Cancer Research 61
- Breast Cancer Treatment Studies 53

Co-authors: Lucia Del Mastro Matteo Lambertini Paolo Bruzzi Gianfilippo Bertelli Pierfranco Conté Alessia Levaggi S. Giraudi Francesca Poggio
Journals: Journal of Clinical Oncology (37 papers)Annals of Oncology (23 papers)Breast Cancer Research and Treatment (10 papers)Oncology (7 papers)Journal of Chemotherapy (6 papers)
Partner nations: Italy United States United Kingdom

In The Last Decade

P. Pronzato

223 papers receiving 4.2k citations

Hit Papers

align trajectories log scale

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade 2022 · 154 citations

Peers

Countries citing papers authored by P. Pronzato

Since Specialization

Citations

This map shows the geographic impact of P. Pronzato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Pronzato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Pronzato more than expected).

Fields of papers citing papers by P. Pronzato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Pronzato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Pronzato. The network helps show where P. Pronzato may publish in the future.

Co-authors

The 25 scholars most cited alongside P. Pronzato, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with P. Pronzato Line = papers co-authored together P. Pronzato links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Descriptive Study of Repeated Hospitalizations and Survival of Patients with Metastatic Melanoma in the Northern Italian Region during 2004–2019 Current Oncology ·Matilde Mannucci, Vincenzo Fontana, Dalila Campanella, Rosangela Filiberti, P. Pronzato, Alessandra Rosa	2023	0
2	The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors Immuno-Oncology Technology ·Andrea Boutros, Roberta Carosio, Dalila Campanella, Francesco Spagnolo, Barbara Banelli, Anna Morabito, Maria Pia Pistillo, Eleonora Croce, Franco Cecchi, P. Pronzato, Paola Queirolo, Edoardo Raposio, V. Fontana, Enrica T. Tanda	2023	3
3	Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives Expert Opinion on Biological Therapy ·Eugenia Cella, Lodovica Zullo, Silvia Marconi, Giovanni Rossi, Simona Coco, Chiara Dellepiane, Angela Alama, Leslie Rozeboom, E. Bennicelli, Francesca Parisi, G. Sacco, Giulia Barletta, Linda Zinoli, Marco Tagliamento, P. Pronzato, Carlo Genova	2022	17
4	Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis Critical Reviews in Oncology/Hematology ·Marco Tagliamento, Elisa Agostinetto, Marco Bruzzone, Marcello Ceppi, Kamal S. Saini, Evandro de Azambuja, Kevin Punie, C. Benedikt Westphalen, Gilberto Morgan, P. Pronzato, Lucia Del Mastro, Francesca Poggio, Matteo Lambertini	2021	44
5	Safety and Efficacy of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Focus on Challenging Populations Immunotherapy ·Lodovica Zullo, Giovanni Rossi, Chiara Dellepiane, Marco Tagliamento, Angela Alama, Simona Coco, Luca Longo, P. Pronzato, Andrea De Maria, Carlo Genova	2021	3
6	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient Cancers ·Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vallome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco, Luca Longo, Lodovica Zullo, Enrica T. Tanda, Chiara Dellepiane, P. Pronzato, Carlo Genova	2020	48
7	Radiomic Detection of EGFR Mutations in NSCLC Cancer Research ·Giovanni Rossi, Emanuele Barabino, Alessandro Fedeli, Gianluca Ficarra, Simona Coco, Alessandro Russo, Vincenzo Adamo, Francesco Buemi, Lodovica Zullo, Mariella Dono, Giuseppa De Luca, Luca Longo, Maria Giovanna Dal Bello, Marco Tagliamento, Angela Alama, Giuseppe Cittadini, P. Pronzato, Carlo Genova	2020	78
8	Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vollome, Claudio Sini, Massimiliano Grassi, (unknown), Simona Coco, Luca Longo, Lodovica Zullo, Enrica T. Tanda, Chiara Dellepiane, P. Pronzato, Carlo Genova	2020	1
9	Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study Oncotarget ·Claudia Bighin, Béatrice Dozin, Francesca Poggio, Marcello Ceppi, Paolo Bruzzi, Alessia D’Alonzo, Alessia Levaggi, S. Giraudi, Matteo Lambertini, Loredana Miglietta, M. Vaglica, Vincenzo Fontana, Giuseppina Iacono, P. Pronzato, Lucia Del Mastro	2017	4
10	Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis The Breast ·Francesca Poggio, Marcello Ceppi, Matteo Lambertini, Paolo Bruzzi, Donatella Ugolini, Claudia Bighin, Alessia Levaggi, S. Giraudi, A. D'Alonzo, M. Vaglica, Eva Blondeaux, M.R. Sertoli, P. Pronzato, Lucia Del Mastro	2017	17
11	The value of hormone serum concentration to predict the gonadotoxic effect of chemotherapy and the efficacy of LHRH analogs as a strategy to reduce treatment-related premature ovarian failure in breast cancer Annals of Oncology ·Giovanni Rossi, Roberta Iadarola, Matteo Lambertini, Francesca Poggio, Alessia Levaggi, Claudia Bighin, S. Giraudi, A. D'Alonzo, S. Pastorino, Eva Blondeaux, A. Abate, G. Iacono, P. Pronzato, Lucia Del Mastro	2015	1
12	Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review Cancer Treatment Reviews ·Fabio Puglisi, Daniel Rea, Michel Kroes, P. Pronzato	2015	7
13	Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis Annals of Oncology ·Matti Aapro, Volker Moebus, Ulrike Nitz, Joyce O’Shaughnessy, P. Pronzato, Michael Untch, Dianne Tomita, Chet Bohac, Brian Leyland‐Jones	2014	21
14	Gene expression profiling in breast cancer: A clinical perspective The Breast ·Grazia Arpino, Daniele Generali, Anna Sapino, Lucia Del Mastro, Antonio Frassoldati, M. De Laurentis, P. Pronzato, Giorgio Mustacchi, Marina Elena Cazzaniga, Sabino De Placido, Pierfranco Conté, Mariarosa Cappelletti, Vanessa Zanoni, Andrea Antonelli, Mario Martinotti, Fabio Puglisi, Alfredo Berruti, Alberto Bottini, Luigi Dogliotti	2013	57
15	Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy Lung Cancer ·Francesco Grossi, Carlo Genova, Nidia Diaz Gaitan, Maria Giovanna Dal Bello, Erika Rijavec, Giulia Barletta, Claudio Sini, C Di Donato, Sabrina Beltramini, P. Pronzato, Gianfranco Porcile, Francesco Boccardo, Stefan Walzer	2013	20
16	Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients Expert Review of Anticancer Therapy ·Lucia Del Mastro, Matteo Lambertini, Claudia Bighin, Alessia Levaggi, Alessia D’Alonzo, S. Giraudi, P. Pronzato	2012	19
17	HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials JNCI Journal of the National Cancer Institute ·Alessandra Gennari, Maria Pia Sormani, P. Pronzato, Matteo Puntoni, Mariantonietta Colozza, Ulrich Pfeffer, Paolo Bruzzi	2007	258
18	Hormonotherapy of advanced prostate cancer Annals of Oncology ·P. Pronzato, M. Rondini	2005	16
19	The Role of Lonidamine in the Treatment of Breast Cancer Patients Annals of the New York Academy of Sciences ·R. Rosso, G. Gardin, P. Pronzato, A. Camoriano, Laura Merlini, C. Naso, M. Rosso, C. Barone, O. Nascimben, Giovanni Pietro Ianniello, F. Sturba, A. Contu, Editta Baldini, Pier Giorgio Giannessi, Pierfranco Conté	1993	2
20	Cisplatin and 5-fluorouracil in refractory breast cancer patients: A phase II study Breast Cancer Research and Treatment ·D. Amoroso, P. Pronzato, Gianfilippo Bertelli, Pietro Gallotti, G Pastorino, Maria Pia Cusimano, Marco Merlano, Pierfranco Conté, Riccardo Rosso	1988	5

About P. Pronzato

P. Pronzato is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics and Reproductive Medicine, having authored 231 papers that have together received 4.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (77 papers), Breast Cancer Treatment Studies (53 papers), Estrogen and related hormone effects (30 papers), Lung Cancer Treatments and Mutations (30 papers), Advanced Breast Cancer Therapies (27 papers), HER2/EGFR in Cancer Research (24 papers), Neutropenia and Cancer Infections (22 papers) and Lung Cancer Research Studies (19 papers). The work is most often cited by research in Oncology (2.5k citations), Reproductive Medicine (632 citations), Cancer Research (1.1k citations), Public Health, Environmental and Occupational Health (887 citations) and Pulmonary and Respiratory Medicine (884 citations). P. Pronzato has collaborated with scholars based in Italy, United States and United Kingdom. Frequent co-authors include Lucia Del Mastro, Matteo Lambertini, Paolo Bruzzi, Gianfilippo Bertelli, Pierfranco Conté, Alessia Levaggi, S. Giraudi, Francesca Poggio, Claudia Bighin and R. Rosso. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Breast Cancer Research and Treatment, Oncology and Journal of Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact